Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This scoping review describes the current use of artificial intelligence in alopecia research, highlighting AI's evolution from diagnostic to prognostic applications in dermatology and identifying gaps in multimodal integration and fairness across demographics.

In this study, researchers developed a novel topical gel combining minoxidil and JAK inhibitor tofacitinib, which effectively enhanced hair follicle growth and reduced local inflammation in mice with alopecia areata, suggesting a new approach for treating this condition.

This study found that the steroidal aromatase inhibitor exemestane stimulated proliferation of human osteoblast cells, suggesting both androgen receptor-dependent and independent pathways are involved.

In this study, artificial intelligence's integration into Indian aesthetic medicine has expanded from consumer apps to crucial roles in diagnostics, treatment planning, and clinic management, driven by demands for precise data over subjective opinions and enhancing competitive advantage.

In this study, researchers observed significantly higher CD8+ T cell levels in Iraqi patients with Alopecia areata compared to healthy controls, alongside concluding that the condition is more prevalent in men.

Antisense oligonucleotides show promise for treating Myotonic Dystrophy type I.

This study suggests that while Nanostring profiling identifies important processes in resolving MA-ARDS, solely targeting late-stage resolution by altering SPM production is not enough. The researchers conclude that combining multi-targeted adjunctive therapies with antimalarial drugs may be necessary to enhance survival and recovery.

This article discusses the term "androgenetic alopecia" proposed to replace "male pattern alopecia," noting its limited use in American dermatology literature.

This review discusses the condition alopecia areata and summarizes its available treatments, mentioning three recently approved Janus kinase inhibitors, but reports no new clinical results.

This study found that PPARα agonists provided protective effects in mouse models of alopecia areata by promoting early reversal of the condition and inhibiting T effector cell function, indicating potential therapeutic value for this inflammatory condition.

In this case report, two adolescents developed androgenetic alopecia after treatment with anastrozole for idiopathic short stature, suggesting this potential side effect should be considered in pediatric patients using aromatase inhibitors.

This study in the United Arab Emirates found that alopecia areata significantly impacts patient quality of life and healthcare resource utilization, particularly among those with higher scalp hair loss.

This report details the case of an 11-year-old girl with APECED syndrome carrying a unique homozygous mutation in the AIRE gene, the first of its kind documented.

This study found that CD44 and CD49d together enhance signaling pathways in lymphocytes in mice with alopecia areata, influencing their activation and function.

This study in a nine-year-old boy from Lebanon identified a gene mutation (c.1066dup p.(Arg356Profs*16)) associated with a rare inborn error of immunity, characterized by craniosynostosis, jaundice, and several other symptoms, expanding the known genotypic and phenotypic spectrum of this condition.

This study found that activating ALDH2, an enzyme that detoxifies acetaldehyde, promoted hair growth in hair follicles by reducing oxidative stress and enhancing cellular signaling pathways, suggesting a potential therapeutic approach for inducing hair regrowth.

This study observed that patients with alopecia areata had significantly higher serum levels of IL-15 and TNF-α compared to controls, with TNF-α levels particularly elevated in individuals with alopecia totalis, though these biomarkers were not influenced by disease duration or activity.

This study found that patients with alopecia areata had significantly higher serum MIF levels compared to healthy controls, which correlated with greater disease severity and duration.

This review discusses the pathophysiology, economic burden, and treatment options of alopecia areata and reports no new clinical results, highlighting the need for better therapies, including JAK inhibitors.

This study found that intramuscular triamcinolone acetonide or pulse therapy effectively treats alopecia areata with manageable side effects, but further strategies are needed to reduce relapse rates.

This study demonstrated that a microarray patch can deliver antibodies in a controlled and prolonged manner, maintaining their functionality after manufacturing and heat exposure, with successful pharmacokinetic proof-of-concept in rats.

In this study, researchers found that patients with severe alopecia areata show varied regrowth timelines with baricitinib, and those with the most severe cases may still experience delayed but eventual improvement.

This study found a significant association between antigliadin antibodies (IgA and IgG) and alopecia areata severity, suggesting a need for celiac disease screening in these patients.

AI and advanced technologies are improving medical diagnostics and treatments.

This study introduces Kalya Research, an AI-driven tool designed to identify and categorize literature on complementary and alternative medicines, showing its effectiveness compared to Medline in finding relevant alopecia research within the context of breast cancer patients.

This study found that Avicennia marina extract significantly increased hair growth in androgenic alopecia patients, suggesting its potential effectiveness by inhibiting 5 alpha-reductase and regulating relevant growth factors.

This case study reports that an infant with maple syrup urine disease developed acrodermatitis dysmetabolica due to low isoleucine levels, and increasing the isoleucine dose improved the condition.

This study suggests that targeting mitophagy to regulate mitochondrial dysfunction and inhibit inflammasome activation could offer a novel therapeutic approach for alopecia areata.

In this study, the rs4541843 G > A variant was found to be significantly associated with increased risk and severity of alopecia areata, as well as elevated expression of hsa-miR-182-5p, suggesting their potential as molecular markers for diagnosis and severity assessment.

In this phase 3 trial, baricitinib showed effectiveness and safety in both adolescents and adults with severe alopecia areata, with adolescents achieving higher response rates despite more severe baseline conditions, suggesting the advantages of early treatment.